Viking Therapeutics Balances Promising Drug Pipeline Against Financial Uncertainty
PILLAR DIAGNOSTIC // WEEK 10
“Despite smooth regulatory and bioequivalence milestones setting up a Q1 2026 autoinjector launch, investor concerns over EPS cuts and R&D burn remain underpriced, likely keeping shares range-bound until cash runway visibility improves.”
Proposed action
Neutral – avoid chasing near-term rallies and monitor upcoming financial milestones.
THE MECHANICS
Tape & flow
—
THE MACHINE
Operational momentum
By 2029, Viking Therapeutics expects to generate $118.5 million in revenue and $12.9 million in earnings while advancing its dual GIPR/GLP-1 agonist VK2735—developed in both oral and subcutaneous forms—into Phase III development for obesity in Q3 2026.
THE MAP
Structure & constraints
Regulatory endpoints have been achieved for VK2809’s Phase 2b NASH and fibrosis study, and bioequivalence work is complete, enabling an autoinjector VK2735 addition to the VANQUISH program in Q1 2026.
THE MOOD
Consensus & positioning
Sharp EPS cuts and mounting R&D losses underscore investor wariness over funding sustainability, even as upbeat Phase 3 timelines, optimistic oral VK2735 outlook, and lofty pipeline-driven fair-value targets sustain a tempered bullish narrative.
